Full-year revenue and EBITDA in line with expectations
Novacyt S.A. (NCYT.L) Approval of COVID-19 test under CTDA legislation
Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 2
Novacyt S.A. (NCYT.L) Proposed accounting treatment of DHSC dispute
Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results
Novacyt S.A. (NCYT.L) Notice of AGM
Paris, France and Camberley, UK – 20 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces that its Annual General Meeting
Novacyt S.A. (NCYT.L) Half Year Update, Investor meeting at 13:00 BST / 14:00 CEST
Paris, France and Camberley, UK – 18 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces a half year update in
Novacyt S.A. (NCYT.L) Notice of investor meeting
Paris, France and Camberley, UK – 5 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), a leading international specialist in clinical diagnostics, announces that it will hold
Novacyt S.A. (NCYT.L) David Allmond to be CEO, Graham Mullis to retire
Paris, France and Camberley, UK – 29 July 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), a leading international specialist in clinical diagnostics, announces the appointment of David
Novacyt S.A. (NCYT.L) Full year 2020 results and update on strategy
Transformational performance in 2020 Continued strong demand for COVID-19 testing in 2021
Novacyt S.A. (NCYT.L) Update on Notice of 2020 Full Year Results
Paris, France and Camberley, UK – 18 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited
Novacyt S.A. (NCYT.L) DHSC Dispute Update
Paris, France and Camberley, UK – 21 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update to its ongoing dispute with
Novacyt S.A. (NCYT.L) Inclusion of SNPsig in the NHS England Framework
Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range